Report Detail
Global Cancer Pain Market Insights, Forecast to 2025
- RnM3480115 |
- 31 May, 2019 |
- Global |
- 116 Pages |
- QYResearch |
- Pharma & Healthcare
Pain in cancer may come from compressing or infiltrating nearby body parts, from treatments and diagnostic procedures or from skin, nerve, and the other changes caused by a hormone imbalance or immune response.
The report, states that opioids will continue to dominate as a breakthrough cancer pain treatment, mostly due to available generics and physician familiarity.
The global Cancer Pain market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cancer Pain market based on company, product type, end user and key regions.
This report studies the global market size of Cancer Pain in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cancer Pain in these regions.
This research report categorizes the global Cancer Pain market by top players/brands, region, type and end user. This report also studies the global Cancer Pain market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
BioDelivery Science
ProStrakan Group
Teva pharmaceuticals
Eli-Lilly
Grunenthal Group
GW Pharmaceuticals
Johnson＆Johnson
Meda Pharmaceuticals
Orexo
Sanofi
WEX Pharmaceuticals
Market size by Product
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
Market size by End User
Paracetamol Treatment-Related Immunotherapy
Radiotherapy
Chemotherapy
Hormone Therapy
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Cancer Pain market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Cancer Pain market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Cancer Pain companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Cancer Pain submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Cancer Pain are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cancer Pain market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Cancer Pain Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Cancer Pain Market Size Growth Rate by Product
- 1.4.2 Opioids
- 1.4.3 Non-Steroidal Anti-Inflammatory Drugs
- 1.4.4 Others
- 1.5 Market by End User
- 1.5.1 Global Cancer Pain Market Size Growth Rate by End User
- 1.5.2 Paracetamol Treatment-Related Immunotherapy
- 1.5.3 Radiotherapy
- 1.5.4 Chemotherapy
- 1.5.5 Hormone Therapy
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Cancer Pain Market Size
- 2.1.1 Global Cancer Pain Revenue 2014-2025
- 2.1.2 Global Cancer Pain Sales 2014-2025
- 2.2 Cancer Pain Growth Rate by Regions
- 2.2.1 Global Cancer Pain Sales by Regions
- 2.2.2 Global Cancer Pain Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Cancer Pain Sales by Manufacturers
- 3.1.1 Cancer Pain Sales by Manufacturers
- 3.1.2 Cancer Pain Sales Market Share by Manufacturers
- 3.1.3 Global Cancer Pain Market Concentration Ratio (CR5 and HHI)
- 3.2 Cancer Pain Revenue by Manufacturers
- 3.2.1 Cancer Pain Revenue by Manufacturers (2014-2019)
- 3.2.2 Cancer Pain Revenue Share by Manufacturers (2014-2019)
- 3.3 Cancer Pain Price by Manufacturers
- 3.4 Cancer Pain Manufacturing Base Distribution, Product Types
- 3.4.1 Cancer Pain Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Cancer Pain Product Type
- 3.4.3 Date of International Manufacturers Enter into Cancer Pain Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Cancer Pain Sales by Product
- 4.2 Global Cancer Pain Revenue by Product
- 4.3 Cancer Pain Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Cancer Pain Breakdown Data by End User
6 North America
- 6.1 North America Cancer Pain by Countries
- 6.1.1 North America Cancer Pain Sales by Countries
- 6.1.2 North America Cancer Pain Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Cancer Pain by Product
- 6.3 North America Cancer Pain by End User
7 Europe
- 7.1 Europe Cancer Pain by Countries
- 7.1.1 Europe Cancer Pain Sales by Countries
- 7.1.2 Europe Cancer Pain Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Cancer Pain by Product
- 7.3 Europe Cancer Pain by End User
8 Asia Pacific
- 8.1 Asia Pacific Cancer Pain by Countries
- 8.1.1 Asia Pacific Cancer Pain Sales by Countries
- 8.1.2 Asia Pacific Cancer Pain Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Cancer Pain by Product
- 8.3 Asia Pacific Cancer Pain by End User
9 Central & South America
- 9.1 Central & South America Cancer Pain by Countries
- 9.1.1 Central & South America Cancer Pain Sales by Countries
- 9.1.2 Central & South America Cancer Pain Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Cancer Pain by Product
- 9.3 Central & South America Cancer Pain by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Cancer Pain by Countries
- 10.1.1 Middle East and Africa Cancer Pain Sales by Countries
- 10.1.2 Middle East and Africa Cancer Pain Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Cancer Pain by Product
- 10.3 Middle East and Africa Cancer Pain by End User
11 Company Profiles
- 11.1 BioDelivery Science
- 11.1.1 BioDelivery Science Company Details
- 11.1.2 Company Business Overview
- 11.1.3 BioDelivery Science Cancer Pain Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 BioDelivery Science Cancer Pain Products Offered
- 11.1.5 BioDelivery Science Recent Development
- 11.2 ProStrakan Group
- 11.2.1 ProStrakan Group Company Details
- 11.2.2 Company Business Overview
- 11.2.3 ProStrakan Group Cancer Pain Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 ProStrakan Group Cancer Pain Products Offered
- 11.2.5 ProStrakan Group Recent Development
- 11.3 Teva pharmaceuticals
- 11.3.1 Teva pharmaceuticals Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Teva pharmaceuticals Cancer Pain Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Teva pharmaceuticals Cancer Pain Products Offered
- 11.3.5 Teva pharmaceuticals Recent Development
- 11.4 Eli-Lilly
- 11.4.1 Eli-Lilly Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Eli-Lilly Cancer Pain Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Eli-Lilly Cancer Pain Products Offered
- 11.4.5 Eli-Lilly Recent Development
- 11.5 Grunenthal Group
- 11.5.1 Grunenthal Group Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Grunenthal Group Cancer Pain Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Grunenthal Group Cancer Pain Products Offered
- 11.5.5 Grunenthal Group Recent Development
- 11.6 GW Pharmaceuticals
- 11.6.1 GW Pharmaceuticals Company Details
- 11.6.2 Company Business Overview
- 11.6.3 GW Pharmaceuticals Cancer Pain Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 GW Pharmaceuticals Cancer Pain Products Offered
- 11.6.5 GW Pharmaceuticals Recent Development
- 11.7 Johnson＆Johnson
- 11.7.1 Johnson＆Johnson Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Johnson＆Johnson Cancer Pain Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Johnson＆Johnson Cancer Pain Products Offered
- 11.7.5 Johnson＆Johnson Recent Development
- 11.8 Meda Pharmaceuticals
- 11.8.1 Meda Pharmaceuticals Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Meda Pharmaceuticals Cancer Pain Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Meda Pharmaceuticals Cancer Pain Products Offered
- 11.8.5 Meda Pharmaceuticals Recent Development
- 11.9 Orexo
- 11.9.1 Orexo Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Orexo Cancer Pain Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Orexo Cancer Pain Products Offered
- 11.9.5 Orexo Recent Development
- 11.10 Sanofi
- 11.10.1 Sanofi Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Sanofi Cancer Pain Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Sanofi Cancer Pain Products Offered
- 11.10.5 Sanofi Recent Development
- 11.11 WEX Pharmaceuticals
12 Future Forecast
- 12.1 Cancer Pain Market Forecast by Regions
- 12.1.1 Global Cancer Pain Sales Forecast by Regions 2019-2025
- 12.1.2 Global Cancer Pain Revenue Forecast by Regions 2019-2025
- 12.2 Cancer Pain Market Forecast by Product
- 12.2.1 Global Cancer Pain Sales Forecast by Product 2019-2025
- 12.2.2 Global Cancer Pain Revenue Forecast by Product 2019-2025
- 12.3 Cancer Pain Market Forecast by End User
- 12.4 North America Cancer Pain Forecast
- 12.5 Europe Cancer Pain Forecast
- 12.6 Asia Pacific Cancer Pain Forecast
- 12.7 Central & South America Cancer Pain Forecast
- 12.8 Middle East and Africa Cancer Pain Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Cancer Pain Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Cancer Pain . Industry analysis & Market Report on Cancer Pain is a syndicated market report, published as Global Cancer Pain Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Cancer Pain market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
